Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Pain Symptom Manage ; 54(5): 701-706.e1, 2017 11.
Article in English | MEDLINE | ID: mdl-28743660

ABSTRACT

CONTEXT: Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose-limiting toxicity of oxaliplatin and affects most colorectal cancer patients. OIPN is commonly evaluated by patient symptom report, using scales to reflect impairment. They do not discriminate between unique grouping of symptoms and signs, which impedes prompt identification of OIPN. OBJECTIVE: The objective of this study was to identify clusters of symptoms and signs that differentiated underlying clinical severity and segregated patients within our population into OIPN subgroups. METHODS: Chemotherapy-naive colorectal cancer patients (N = 148) receiving oxaliplatin were administered the Total Neuropathy Score clinical (TNSc©), which includes symptom report (sensory, motor, autonomic) and sensory examination (pin sense, vibration, reflexes). The TNSc was administered before chemotherapy initiation (T0) and after cumulative doses of oxaliplatin 510-520 mg/m2 (T1) and 1020-1040 mg/m2 of oxaliplatin (T2). Using mean T2 TNSc scores, latent class analysis grouped patients into OIPN severity cohorts. RESULTS: Latent class analysis categorized patients into four distinct OIPN groups: low symptoms and low signs (n = 54); low symptoms and intermediate signs (n = 44); low symptoms and high signs (n = 21); and high symptoms and high signs (n = 29). No differences were noted among OIPN groups on age, sex, chemotherapy regimen, or cumulative oxaliplatin dose. CONCLUSION: We identified OIPN patient groups with distinct symptoms/signs, demonstrating variability of OIPN presentation regardless of cumulative oxaliplatin dose. Over half of the sample had positive findings on OIPN examination despite little or no symptoms. Sensory examination of all patients receiving oxaliplatin is indicated for timely identification of OIPN, which will allow earlier symptom management.


Subject(s)
Antineoplastic Agents/toxicity , Colorectal Neoplasms/drug therapy , Neurotoxicity Syndromes/classification , Organoplatinum Compounds/toxicity , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/classification , Antineoplastic Agents/therapeutic use , Colorectal Neoplasms/physiopathology , Female , Humans , Male , Middle Aged , Neurologic Examination , Neurotoxicity Syndromes/diagnosis , Neurotoxicity Syndromes/physiopathology , Organoplatinum Compounds/therapeutic use , Oxaliplatin , Peripheral Nervous System Diseases/diagnosis , Peripheral Nervous System Diseases/physiopathology , Prospective Studies , Severity of Illness Index
2.
Neurotoxicology ; 48: 35-43, 2015 May.
Article in English | MEDLINE | ID: mdl-25757834

ABSTRACT

INTRODUCTION: Delayed neurologic sequelae (DNS) after carbon monoxide (CO) poisoning manifest as a relapse of neurologic deficits. However, the long-term outcome of DNS has not been fully clarified. Myelin basic protein (MBP) levels in the cerebrospinal fluid (CSF) have been reported to be elevated in DNS. However, the precise timing and clinical value of the CSF examination have not been fully evaluated. We aimed to clarify the long-term outcome and the factors predicting the outcome of DNS and to evaluate the utility of CSF-MBP for predicting the development and severity of DNS. METHODS: This work was designed as a single-center, prospective, observational study. We graded DNS severity as Grade 1 (consistent independence), Grade 2 (temporary dependence), or Grade 3 (persistent dependence). We analyzed the percentage categorized in each grade and the parameters associated with outcome. RESULTS: Of 100 patients experiencing acute CO poisoning (median age: 46 years; 69% male), 20 (20%) developed DNS, including six Grade 1 (30%), ten Grade 2 (50%), and four Grade 3 (20%) cases. The Grade 3 patients [median: 77 years; interquartile range (IQR): 76-82] were older than the Grade 1 patients [42; 30-46] (P<0.01); the DNS onset of the Grade 1 patients [median interval after poisoning: 35 days; IQR: 32-56] occurred later than that of the Grade 3 patients [10; 9-13] P<0.001) and the Grade 2 patients [25; 23-27] (P<0.05). The CSF-MBP levels of the DNS patients were higher than those of the non-DNS patients (P<0.0001). The 1-month CSF-MBP levels of the Grade 3 patients were higher than those of the Grade 1 patients (P<0.05); the MBP index, defined as [(Age)×(1-month CSF-MBP)], was higher in the Grade 3 patients than in the Grade 1 patients (P<0.01). Severe DNS were associated with advanced age (>72.5 years), earlier onset (<18 days), higher 1-month CSF-MBP (>252 pg/ml), and higher MBP index (>20.9 year × ng/ml). CONCLUSIONS: Poor DNS outcomes were associated with advanced age and earlier onset. CSF-MBP can serve as a sensitive predictor of both the development and outcomes of DNS.


Subject(s)
Carbon Monoxide Poisoning/diagnosis , Neurotoxicity Syndromes/diagnosis , Acute Disease , Adult , Age Factors , Aged , Aged, 80 and over , Biomarkers/cerebrospinal fluid , Carbon Monoxide Poisoning/cerebrospinal fluid , Carbon Monoxide Poisoning/classification , Carbon Monoxide Poisoning/complications , Female , Humans , Japan , Magnetic Resonance Imaging , Male , Middle Aged , Myelin Basic Protein/cerebrospinal fluid , Neurotoxicity Syndromes/cerebrospinal fluid , Neurotoxicity Syndromes/classification , Neurotoxicity Syndromes/etiology , Predictive Value of Tests , Prognosis , Prospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Time Factors , Young Adult
3.
Anesth Analg ; 120(3): 649-652, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25695580

ABSTRACT

To learn the latest developments in the various forms of postoperative cognitive dysfunction, a group of scientists and physicians met in Stockholm for a full day of presentations and interactive discussions. This article summarizes the discussion; highlighting progress, challenges, and new directions in the area of perioperative neurotoxicity in our aging population.


Subject(s)
Cognition Disorders , Neurotoxicity Syndromes , Perioperative Period , Postoperative Complications , Age Factors , Animals , Biomarkers/analysis , Cognition Disorders/classification , Cognition Disorders/diagnosis , Cognition Disorders/epidemiology , Cognition Disorders/psychology , Humans , Neurotoxicity Syndromes/classification , Neurotoxicity Syndromes/diagnosis , Neurotoxicity Syndromes/epidemiology , Neurotoxicity Syndromes/psychology , Postoperative Complications/classification , Postoperative Complications/diagnosis , Postoperative Complications/epidemiology , Postoperative Complications/psychology , Predictive Value of Tests , Prognosis , Risk Factors , Terminology as Topic
5.
Neurotoxicol Teratol ; 34(4): 413-24, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22729072

ABSTRACT

Rodents are widely used to test the developmental neurotoxicity potential of chemical substances. The regulatory test procedures are elaborate and the requirement of numerous animals is ethically disputable. Therefore, non-animal alternatives are highly desirable, but appropriate test systems that meet regulatory demands are not yet available. Hence, we have developed a new developmental neurotoxicity assay based on specific whole-mount immunostainings of primary and secondary motor neurons (using the monoclonal antibodies znp1 and zn8) in zebrafish embryos. By classifying the motor neuron defects, we evaluated the severity of the neurotoxic damage to individual primary and secondary motor neurons caused by chemical exposure and determined the corresponding effect concentration values (EC50). In a proof-of-principle study, we investigated the effects of three model compounds thiocyclam, cartap and disulfiram, which show some neurotoxicity-indicating effects in vertebrates, and the positive controls ethanol and nicotine and the negative controls 3,4-dichloroaniline (3,4-DCA) and triclosan. As a quantitative measure of the neurotoxic potential of the test compounds, we calculated the ratios of the EC50 values for motor neuron defects and the cumulative malformations, as determined in a zebrafish embryo toxicity test (zFET). Based on this index, disulfiram was classified as the most potent and thiocyclam as the least potent developmental neurotoxin. The index also confirmed the control compounds as positive and negative neurotoxicants. Our findings demonstrate that this index can be used to reliably distinguish between neurotoxic and non-neurotoxic chemicals and provide a sound estimate for the neurodevelopmental hazard potential of a chemical. The demonstrated method can be a feasible approach to reduce the number of animals used in developmental neurotoxicity evaluation procedures.


Subject(s)
Animal Use Alternatives/methods , Motor Neuron Disease/chemically induced , Motor Neuron Disease/classification , Neurotoxins/toxicity , Toxicity Tests/methods , Animals , Disease Models, Animal , Embryo, Nonmammalian/drug effects , Embryo, Nonmammalian/embryology , Female , Male , Neurotoxicity Syndromes/classification , Neurotoxins/chemistry , Zebrafish
6.
Med Tr Prom Ekol ; (7): 21-6, 2009.
Article in Russian | MEDLINE | ID: mdl-19715221

ABSTRACT

The review covers contemporary views of chronic occupational toxic encephalopathies pathogenesis and classifications of these occupational disorders. Pathophysiologic viewpoints on development and course of chronic brain disorders are presented, general mechanisms of vascular and toxic encephalopathies are considered.


Subject(s)
Neurotoxicity Syndromes , Neurotoxins/adverse effects , Occupational Diseases , Occupational Exposure/adverse effects , Humans , Morbidity , Neurotoxicity Syndromes/classification , Neurotoxicity Syndromes/epidemiology , Neurotoxicity Syndromes/etiology , Occupational Diseases/classification , Occupational Diseases/epidemiology , Occupational Diseases/etiology , Russia/epidemiology
7.
Neurotoxicology ; 30 Suppl 1: S17-31, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19766671

ABSTRACT

Neurotoxicity and mechanistic data were collected for six alpha-cyano pyrethroids (beta-cyfluthrin, cypermethrin, deltamethrin, esfenvalerate, fenpropathrin and lambda-cyhalothrin) and up to six non-cyano containing pyrethroids (bifenthrin, S-bioallethrin [or allethrin], permethrin, pyrethrins, resmethrin [or its cis-isomer, cismethrin] and tefluthrin under standard conditions. Factor analysis and multivariate dissimilarity analysis were employed to evaluate four independent data sets comprised of (1) fifty-six behavioral and physiological parameters from an acute neurotoxicity functional observatory battery (FOB), (2) eight electrophysiological parameters from voltage clamp experiments conducted on the Na(v)1.8 sodium channel expressed in Xenopus oocytes, (3) indices of efficacy, potency and binding calculated for calcium ion influx across neuronal membranes, membrane depolarization and glutamate released from rat brain synaptosomes and (4) changes in chloride channel open state probability using a patch voltage clamp technique for membranes isolated from mouse neuroblastoma cells. The pyrethroids segregated into Type I (T--syndrome-tremors) and Type II (CS syndrome--choreoathetosis with salivation) groups based on FOB data. Of the alpha-cyano pyrethroids, deltamethrin, lambda-cyhalothrin, cyfluthrin and cypermethrin arrayed themselves strongly in a dose-dependent manner along two factors that characterize the CS syndrome. Esfenvalerate and fenpropathrin displayed weaker response profiles compared to the non-cyano pyrethroids. Visual clustering on multidimensional scaling (MDS) maps based upon sodium ion channel and calcium influx and glutamate release dissimilarities gave similar groupings. The non-cyano containing pyrethroids were arrayed in a dose-dependent manner along two different factors that characterize the T-syndrome. Bifenthrin was an outlier when MDS maps of the non-cyano pyrethroids were based on sodium ion channel characteristics and permethrin was an outlier when the MDS maps were based on calcium influx/glutamate release potency. Four of six alpha-cyano pyrethroids (lambda-cyfluthrin, cypermethrin, deltamethrin and fenpropathrin) reduced open chloride channel probability. The R-isomers of lambda-l-cyhalothrin reduced open channel probability whereas the S-isomers, antagonized the action of the R-isomers. None of the non-cyano pyrethroids reduced open channel probability, except bioallethrin, which gave a weak response. Overall, based upon neurotoxicity data and the effect of pyrethroids on sodium, calcium and chloride ion channels, it is proposed that bioallethrin, cismethrin, tefluthrin, bifenthrin and permethrin belong to one common mechanism group and deltamethrin, lambda-cyhalothrin, cyfluthrin and cypermethrin belong to a second. Fenpropathrin and esfenvalerate occupy an intermediate position between these two groups.


Subject(s)
Insecticides/toxicity , Neurotoxicity Syndromes/classification , Neurotoxicity Syndromes/etiology , Pyrethrins/classification , Pyrethrins/toxicity , Animals , Brain/ultrastructure , Calcium/metabolism , Cell Line, Tumor , Disease Models, Animal , Factor Analysis, Statistical , Glutamic Acid/metabolism , Insecticides/classification , Ion Channel Gating/drug effects , Ion Channels/classification , Ion Channels/drug effects , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Neuroblastoma/pathology , Neurotoxicity Syndromes/physiopathology , Oocytes , Patch-Clamp Techniques , Principal Component Analysis , Rats , Synaptosomes/drug effects , Synaptosomes/physiology , Xenopus
8.
Semin Neurol ; 28(4): 495-510, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18843577

ABSTRACT

Imaging of the brain, magnetic resonance imaging (MRI) in particular, is a key adjunctive tool in the diagnosis and management of toxic-metabolic disorders such as alcoholism, mitochondrial encephalopathies, disorders of iron or copper metabolism, exposure to carbon monoxide, radiotherapy, immunosuppressive agents, toluene, and recreational drugs. In this article, we review the neuroimaging findings of common toxic and metabolic disorders focusing on the role of conventional MRI. We also consider advanced imaging methods, such as magnetic resonance spectroscopy, diffusion MRI, and positron emission tomography. We hope this article will prove useful to trainees and practitioners in the clinical and imaging fields of the neurosciences.


Subject(s)
Diagnostic Imaging , Metabolic Diseases/diagnosis , Neurotoxicity Syndromes/diagnosis , Brain Mapping , Diagnostic Imaging/classification , Humans , Metabolic Diseases/drug therapy , Neurotoxicity Syndromes/classification , Neurotoxicity Syndromes/drug therapy
10.
Neurol Clin ; 18(3): 517-24, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10873228

ABSTRACT

An ideal classification of neurotoxic substances should link the vulnerable target of chemical attack to alterations in neural function. There is little basis for classifying agents based on their common use or physico-chemical properties. Outlined in this article are the principal cellular targets of substances that perturb the nervous system structure and function.


Subject(s)
Myelin Sheath/drug effects , Neuroglia/drug effects , Neurons/drug effects , Neurotoxicity Syndromes/classification , Neurotoxins/classification , Animals , Humans , Neurotoxicity Syndromes/diagnosis , Neurotoxins/toxicity , Rats
11.
Neurol Clin ; 18(3): 525-40, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10873229

ABSTRACT

Neurotoxic injury to the nervous system produces neuronal death or distal axonal degeneration. Neurotoxin-induced demyelination is relatively rare in the peripheral and central nervous systems. Major advances have occurred in our understanding of the mechanisms of apoptotic cell death. The pathways leading to apoptosis offer many new approaches to neuroprotection.


Subject(s)
Apoptosis/drug effects , Neurotoxicity Syndromes/etiology , Neurotoxins/adverse effects , Animals , Demyelinating Diseases/chemically induced , Humans , Nerve Degeneration/chemically induced , Neuroglia/drug effects , Neurons/drug effects , Neurotoxicity Syndromes/classification , Neurotoxins/classification
12.
Neurol Clin ; 18(3): 541-62, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10873230

ABSTRACT

In this article, the authors provide a conceptual framework in which to consider alternative approaches to identify the developmental consequences of exposing the developing brain to neurotoxic substances. Concepts underlying brain development and issues regarding neurobehavioral testing in children are reviewed. In addition, the authors selectively review preclinical data identifying mechanisms contributing to neurobehavioral compromise, and clinical data identifying deficits resulting from exposure to two classes of neurotoxins: exposure to drugs of abuse, including alcohol, nicotine, and cocaine; and exposure to environmental agents, including lead, methyl-mercury, PCBs, and organophosphorus compounds.


Subject(s)
Developmental Disabilities/chemically induced , Neurotoxicity Syndromes/etiology , Neurotoxins/adverse effects , Brain/drug effects , Child , Child, Preschool , Developmental Disabilities/classification , Developmental Disabilities/diagnosis , Female , Humans , Infant , Infant, Newborn , Male , Neurotoxicity Syndromes/classification , Neurotoxicity Syndromes/diagnosis , Neurotoxins/classification , Pregnancy , Prenatal Exposure Delayed Effects
13.
Eur Radiol ; 9(9): 1916-8, 1999.
Article in English | MEDLINE | ID: mdl-10602976

ABSTRACT

Cyclosporin A, an immunosuppressive agent, is known to have neurotoxic effects, but until now, there has not been agreement on the underlying mechanism. Our report suggests, by using diffusion-weighted MRI, that the brain lesions caused by cyclosporin A, are probably related to vasogenic edema. This may explain the complete recovery of the lesions on imaging when cyclosporine therapy is stopped.


Subject(s)
Brain Edema/classification , Brain/pathology , Cyclosporine/adverse effects , Immunosuppressive Agents/adverse effects , Magnetic Resonance Imaging/methods , Neurotoxicity Syndromes/diagnosis , Adult , Bone Marrow Transplantation , Brain/drug effects , Brain Edema/chemically induced , Brain Edema/diagnosis , Diffusion , Graft vs Host Disease/prevention & control , Humans , Male , Neurotoxicity Syndromes/classification , Neurotoxicity Syndromes/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...